KalVista Pharmaceuticals (KALV)
(Delayed Data from NSDQ)
$14.47 USD
-0.92 (-5.98%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $14.49 +0.02 (0.14%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for KalVista Pharmaceuticals, Inc falls in the month of April.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
4/30/2024 | 4/30/2023 | 4/30/2022 | 4/30/2021 | 4/30/2020 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -126.64 | -92.91 | -82.34 | -46.24 | -29.12 |
Depreciation/Amortization & Depletion | 0.91 | 1.71 | 3.13 | 1.22 | 0.71 |
Net Change from Assets/Liabilities | 15.17 | 7.41 | -12.32 | 8.35 | -20.64 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 21.34 | 8.53 | 13.40 | 6.51 | 4.24 |
Net Cash From Operating Activities | -89.23 | -75.26 | -78.13 | -30.17 | -44.82 |
Property & Equipment | -0.44 | -1.20 | -0.93 | -0.08 | -0.22 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -84.28 | 42.61 | 58.79 | -147.57 | 16.97 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -84.72 | 41.42 | 57.86 | -147.65 | 16.75 |
Uses of Funds
4/30/2024 | 4/30/2023 | 4/30/2022 | 4/30/2021 | 4/30/2020 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 150.71 | 58.12 | 1.58 | 212.12 | 11.64 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | -0.05 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 150.71 | 58.12 | 1.58 | 212.12 | 11.58 |
Effect of Exchange Rate Changes | -1.21 | 1.24 | -1.17 | 0.51 | 0.26 |
Net Change In Cash & Equivalents | -24.45 | 25.51 | -19.86 | 34.80 | -16.22 |
Cash at Beginning of Period | 56.24 | 30.73 | 50.59 | 15.79 | 32.01 |
Cash at End of Period | 31.79 | 56.24 | 30.73 | 50.59 | 15.79 |
Diluted Net EPS | -3.44 | -3.33 | -3.36 | -2.42 | -1.64 |
Fiscal Year End for KalVista Pharmaceuticals, Inc falls in the month of April.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
4/30/2024 | 1/31/2024 | 10/31/2023 | 7/31/2023 | 4/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -126.64 | -82.00 | -52.97 | -25.32 | -92.91 |
Depreciation/Amortization & Depletion | 0.91 | 0.69 | 0.47 | 0.26 | 1.71 |
Net Change from Assets/Liabilities | 15.17 | -1.44 | -0.41 | -4.22 | 7.41 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 21.34 | 8.63 | 6.35 | 2.55 | 8.53 |
Net Cash From Operating Activities | -89.23 | -74.13 | -46.56 | -26.73 | -75.26 |
Property & Equipment | -0.44 | -0.03 | -0.01 | -0.01 | -1.20 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -84.28 | 41.79 | 48.38 | 19.62 | 42.61 |
Other Investing Activities | 0.00 | -0.29 | -0.20 | 0.00 | 0.00 |
Net Cash from Investing Activities | -84.72 | 41.47 | 48.17 | 19.61 | 41.42 |
Uses of Funds
4/30/2024 | 1/31/2024 | 10/31/2023 | 7/31/2023 | 4/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 150.71 | 0.62 | 0.33 | 0.20 | 58.12 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 150.71 | 0.62 | 0.33 | 0.20 | 58.12 |
Effect of Exchange Rate Changes | -1.21 | -1.14 | -0.52 | 0.08 | 1.24 |
Net Change In Cash & Equivalents | -24.45 | -33.18 | 1.43 | -6.83 | 25.51 |
Cash at Beginning of Period | 56.24 | 56.24 | 56.24 | 56.24 | 30.73 |
Cash at End of Period | 31.79 | 23.06 | 57.67 | 49.41 | 56.24 |
Diluted Net EPS | -1.06 | -0.84 | -0.80 | -0.74 | -0.74 |